메뉴 건너뛰기




Volumn 52, Issue 2, 2014, Pages 392-397

Performance of Vitek 2 for antimicrobial susceptibility testing of Staphylococcus spp. and Enterococcus spp.

Author keywords

[No Author keywords available]

Indexed keywords

CEFOXITIN; CIPROFLOXACIN; CLINDAMYCIN; COTRIMOXAZOLE; DALFOPRISTIN PLUS QUINUPRISTIN; DAPTOMYCIN; ERYTHROMYCIN; GENTAMICIN; LINEZOLID; NITROFURANTOIN; OXACILLIN; PENICILLIN DERIVATIVE; RIFAMPICIN; TIGECYCLINE; VANCOMYCIN;

EID: 84893144215     PISSN: 00951137     EISSN: 1098660X     Source Type: Journal    
DOI: 10.1128/JCM.02432-13     Document Type: Article
Times cited : (64)

References (27)
  • 2
    • 77950509581 scopus 로고    scopus 로고
    • Performance of an agar dilution method and a Vitek 2 card for detection of inducible clindamycin resistance in Staphylococcus spp
    • Lavallée C, Rouleau D, Gaudreau C, Roger M, Tsimiklis C, Locas MC, Gagnon S, Delorme J, Labbé A. 2010. Performance of an agar dilution method and a Vitek 2 card for detection of inducible clindamycin resistance in Staphylococcus spp. J. Clin. Microbiol. 48:1354-1357. http://dx.doi.org/10.1128/ JCM.01751-09.
    • (2010) J. Clin. Microbiol. , vol.48 , pp. 1354-1357
    • Lavallée, C.1    Rouleau, D.2    Gaudreau, C.3    Roger, M.4    Tsimiklis, C.5    Locas, M.C.6    Gagnon, S.7    Delorme, J.8    Labbé, A.9
  • 3
    • 84856612590 scopus 로고    scopus 로고
    • Comparison of BD Phoenix and bioMérieux Vitek 2 automated systems for the detection of macrolide-lincosamide-streptogramin B resistance among clinical isolates of Staphylococcus
    • Buchan BW, Anderson NW, Ledeboer NA. 2012. Comparison of BD Phoenix and bioMérieux Vitek 2 automated systems for the detection of macrolide-lincosamide-streptogramin B resistance among clinical isolates of Staphylococcus. Diagn. Microbiol. Infect. Dis. 72:291-294. http://dx.doi.org/10. 1016/j.diagmicrobio.2011.12.003.
    • (2012) Diagn. Microbiol. Infect. Dis. , vol.72 , pp. 291-294
    • Buchan, B.W.1    Anderson, N.W.2    Ledeboer, N.A.3
  • 4
    • 77952983015 scopus 로고    scopus 로고
    • Analysis of methods commonly used for glycopeptide and oxazolidinone susceptibility testing in Enterococcus faecium isolates
    • Raponi G, Ghezzi MC, Gherardi G, Lorino G, Dicuonzo G. 2010. Analysis of methods commonly used for glycopeptide and oxazolidinone susceptibility testing in Enterococcus faecium isolates. J. Med. Microbiol. 59:672-678. http://dx.doi.org/10.1099/jmm.0.016444-0.
    • (2010) J. Med. Microbiol. , vol.59 , pp. 672-678
    • Raponi, G.1    Ghezzi, M.C.2    Gherardi, G.3    Lorino, G.4    Dicuonzo, G.5
  • 6
    • 12144260815 scopus 로고    scopus 로고
    • Detection of inducible clindamycin resistance of staphylococci in conjunction with performance of automated broth susceptibility testing
    • Jorgensen JH, Crawford SA, McElmeel ML, Fiebelkorn KR. 2004. Detection of inducible clindamycin resistance of staphylococci in conjunction with performance of automated broth susceptibility testing. J. Clin. Microbiol. 42: 1800-1802. http://dx.doi.org/10.1128/JCM.42.4.1800-1802.2004.
    • (2004) J. Clin. Microbiol. , vol.42 , pp. 1800-1802
    • Jorgensen, J.H.1    Crawford, S.A.2    McElmeel, M.L.3    Fiebelkorn, K.R.4
  • 8
    • 84873859337 scopus 로고    scopus 로고
    • Inducible resistance to clindamycin in Staphylococcus aureus: Validation of Vitek-2 against CLSI D-test
    • Gardiner BJ, Grayson ML, Wood GM. 2013. Inducible resistance to clindamycin in Staphylococcus aureus: validation of Vitek-2 against CLSI D-test. Pathology 45:181184. http://dx.doi.org/10.1097/PAT.0b013e32835cccda.
    • (2013) Pathology , vol.45 , pp. 181184
    • Gardiner, B.J.1    Grayson, M.L.2    Wood, G.M.3
  • 9
    • 84893117416 scopus 로고    scopus 로고
    • bioMérieux. 2013. VITEK 2 AST-GP71 product information. bioMérieux, Inc., Durham, NC.
    • bioMérieux. 2013. VITEK 2 AST-GP71 product information. bioMérieux, Inc., Durham, NC.
  • 10
    • 84893066557 scopus 로고    scopus 로고
    • bioMérieux. 2013. VITEK 2 AST-GP72 product information. bioMérieux, Inc., Durham, NC.
    • bioMérieux. 2013. VITEK 2 AST-GP72 product information. bioMérieux, Inc., Durham, NC.
  • 13
    • 23744453764 scopus 로고    scopus 로고
    • Analysis of the comparative workflow and performance characteristics of the VITEK 2 and Phoenix systems
    • Eigner U, Schmid A, Wild U, Bertsch D, Fahr AM. 2005. Analysis of the comparative workflow and performance characteristics of the VITEK 2 and Phoenix systems. J. Clin. Microbiol. 43:3829-3834. http://dx.doi.org/10.1128/JCM.43.8. 3829-3834.2005.
    • (2005) J. Clin. Microbiol. , vol.43 , pp. 3829-3834
    • Eigner, U.1    Schmid, A.2    Wild, U.3    Bertsch, D.4    Fahr, A.M.5
  • 14
    • 0034884831 scopus 로고    scopus 로고
    • Clindamycin treatment of Staphylococcus aureus expressing inducible clindamycin resistance
    • Drinkovic D, Fuller ER, Shore KP, Holland DJ, Ellis-Pegler R. 2001. Clindamycin treatment of Staphylococcus aureus expressing inducible clindamycin resistance. J. Antimicrob. Chemother. 48:315-316. http://dx.doi.org/10.1093/jac/ 48.2.315.
    • (2001) J. Antimicrob. Chemother. , vol.48 , pp. 315-316
    • Drinkovic, D.1    Fuller, E.R.2    Shore, K.P.3    Holland, D.J.4    Ellis-Pegler, R.5
  • 15
    • 0242574929 scopus 로고    scopus 로고
    • Failure of clindamycin treatment of methicillin-resistant Staphylococcus aureus expressing inducible clindamycin resistance in vitro
    • Siberry GK, Tekle T, Carroll K, Dick J. 2003. Failure of clindamycin treatment of methicillin-resistant Staphylococcus aureus expressing inducible clindamycin resistance in vitro. Clin. Infect. Dis. 37:1257-1260. http://dx.doi.org/10.1086/377501.
    • (2003) Clin. Infect. Dis. , vol.37 , pp. 1257-1260
    • Siberry, G.K.1    Tekle, T.2    Carroll, K.3    Dick, J.4
  • 17
    • 79960950114 scopus 로고    scopus 로고
    • Adherence to CLSI recommendations for testing of Staphylococcus aureus isolates in Louisiana hospitals: Report of a clinical failure and results of a questionnaire study
    • Patra KP, Vanchiere JA, Bocchini JA. 2011. Adherence to CLSI recommendations for testing of Staphylococcus aureus isolates in Louisiana hospitals: report of a clinical failure and results of a questionnaire study. J. Clin. Microbiol. 49:3019-3020. http://dx.doi.org/10.1128/JCM.00944-11.
    • (2011) J. Clin. Microbiol. , vol.49 , pp. 3019-3020
    • Patra, K.P.1    Vanchiere, J.A.2    Bocchini, J.A.3
  • 18
    • 15944426803 scopus 로고    scopus 로고
    • Prevalence of inducible clindamycin resistance in macrolide-resistant Staphylococcus spp
    • Fokas S, Tsironi M, Kalkani M, Dionysopouloy M. 2005. Prevalence of inducible clindamycin resistance in macrolide-resistant Staphylococcus spp. Clin. Microbiol. Infect. 11:337-340. http://dx.doi.org/10.1111/j.1469-0691.2005. 01101.x.
    • (2005) Clin. Microbiol. Infect. , vol.11 , pp. 337-340
    • Fokas, S.1    Tsironi, M.2    Kalkani, M.3    Dionysopouloy, M.4
  • 19
    • 33746211170 scopus 로고    scopus 로고
    • Prevalence of inducible clindamycin resistance among community-and hospitalassociated Staphylococcus aureus isolates
    • Patel M, Waites KB, Moser SA, Cloud GA, Hoesley CJ. 2006. Prevalence of inducible clindamycin resistance among community-and hospitalassociated Staphylococcus aureus isolates. J. Clin. Microbiol. 44:2481-2484. http://dx.doi.org/10.1128/JCM.02582-05.
    • (2006) J. Clin. Microbiol. , vol.44 , pp. 2481-2484
    • Patel, M.1    Waites, K.B.2    Moser, S.A.3    Cloud, G.A.4    Hoesley, C.J.5
  • 20
    • 2942564178 scopus 로고    scopus 로고
    • Incidence of constitutive and inducible clindamycin resistance in Staphylococcus aureus and coagulase-negative staphylococci in a community and a tertiary care hospital
    • Schreckenberger PC, Ilendo E, Ristow KL. 2004. Incidence of constitutive and inducible clindamycin resistance in Staphylococcus aureus and coagulase-negative staphylococci in a community and a tertiary care hospital. J. Clin. Microbiol. 42:2777-2779. http://dx.doi.org/10.1128/JCM.42.6.2777-2779. 2004.
    • (2004) J. Clin. Microbiol. , vol.42 , pp. 2777-2779
    • Schreckenberger, P.C.1    Ilendo, E.2    Ristow, K.L.3
  • 21
    • 33847670929 scopus 로고    scopus 로고
    • Detection and prevalence of inducible clindamycin resistance in staphylococci
    • Yilmaz G, Aydin K, Iskender S, Caylan R, Koksal I. 2007. Detection and prevalence of inducible clindamycin resistance in staphylococci. J. Med. Microbiol. 56:342-345. http://dx.doi.org/10.1099/jmm.0.46761-0.
    • (2007) J. Med. Microbiol. , vol.56 , pp. 342-345
    • Yilmaz, G.1    Aydin, K.2    Iskender, S.3    Caylan, R.4    Koksal, I.5
  • 22
    • 84864439400 scopus 로고    scopus 로고
    • Should laboratories test methicillinresistant Staphylococcus aureus for elevated vancomycin minimum inhibitory concentrations by Etest as a driver of treatment changes?
    • Humphries RM, Hindler JA. 2012. Should laboratories test methicillinresistant Staphylococcus aureus for elevated vancomycin minimum inhibitory concentrations by Etest as a driver of treatment changes? Clin. Infect. Dis. 55:612-613. http://dx.doi.org/10.1093/cid/cis469.
    • (2012) Clin. Infect. Dis. , vol.55 , pp. 612-613
    • Humphries, R.M.1    Hindler, J.A.2
  • 23
    • 84455170136 scopus 로고    scopus 로고
    • VraSR two-component regulatory system contributes to mprF-mediated decreased susceptibility to daptomycin in in vivoselected clinical strains of methicillin-resistant Staphylococcus aureus
    • Mehta S, Cuirolo AX, Plata KB, Riosa S, Silverman JA, Rubio A, Rosato RR, Rosato AE. 2012. VraSR two-component regulatory system contributes to mprF-mediated decreased susceptibility to daptomycin in in vivoselected clinical strains of methicillin-resistant Staphylococcus aureus. Antimicrob. Agents Chemother. 56:92-102. http://dx.doi.org/10.1128/AAC.00432-10.
    • (2012) Antimicrob. Agents Chemother. , vol.56 , pp. 92-102
    • Mehta, S.1    Cuirolo, A.X.2    Plata, K.B.3    Riosa, S.4    Silverman, J.A.5    Rubio, A.6    Rosato, R.R.7    Rosato, A.E.8
  • 24
    • 79951833552 scopus 로고    scopus 로고
    • Daptomycin nonsusceptible enterococci: An emerging challenge for clinicians
    • Kelesidis T, Humphries R, Uslan DZ, Pegues DA. 2011. Daptomycin nonsusceptible enterococci: an emerging challenge for clinicians. Clin. Infect. Dis. 52:228-234. http://dx.doi.org/10.1093/cid/ciq113.
    • (2011) Clin. Infect. Dis. , vol.52 , pp. 228-234
    • Kelesidis, T.1    Humphries, R.2    Uslan, D.Z.3    Pegues, D.A.4
  • 25
    • 84868018494 scopus 로고    scopus 로고
    • Genotypic and phenotypic evaluation of the evolution of high-level daptomycin nonsusceptibility in vancomycin-resistant Enterococcus faecium
    • Humphries RM, Kelesidis T, Tewhey R, Rose WE, Schork N, Nizet V, Sakoulas G. 2012. Genotypic and phenotypic evaluation of the evolution of high-level daptomycin nonsusceptibility in vancomycin-resistant Enterococcus faecium. Antimicrob. Agents Chemother. 56:6051-6053. http://dx.doi.org/10.1128/AAC.01318- 12.
    • (2012) Antimicrob. Agents Chemother. , vol.56 , pp. 6051-6053
    • Humphries, R.M.1    Kelesidis, T.2    Tewhey, R.3    Rose, W.E.4    Schork, N.5    Nizet, V.6    Sakoulas, G.7
  • 26
    • 84880763052 scopus 로고    scopus 로고
    • Evolution of high-level daptomycin resistance in Enterococcus faecium during daptomycin therapy is associated with limited mutations in the bacterial genome
    • Kelesidis T, Tewhey R, Humphries RM. 2013. Evolution of high-level daptomycin resistance in Enterococcus faecium during daptomycin therapy is associated with limited mutations in the bacterial genome. J. Antimicrob. Chemother. 68:1926-1928. http://dx.doi.org/10.1093/jac/dkt117.
    • (2013) J. Antimicrob. Chemother. , vol.68 , pp. 1926-1928
    • Kelesidis, T.1    Tewhey, R.2    Humphries, R.M.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.